Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Daniel Nomura
AddedFeb 13, 2024
UpdatedMay 31, 2026
Daniel Nomura

Daniel Nomura

Board Member, Vicinitas Therapeutics

CrunchbaseLinkedInThe Org

Daniel Nomura's Career

Vicinitas Therapeutics
Vicinitas Therapeutics

San Francisco, CA, US

Board Member· Board
Frontier Medicines
Frontier Medicines

South San Francisco, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Daniel Nomura's Career

Vicinitas Therapeutics
Vicinitas Therapeutics
Series A$65M232022San Francisco, CA, US
Board Member· Board

Leadership at Vicinitas Therapeutics

Christian HofmannChristian HofmannBoard Member
Jorge CondeJorge CondeBoard Member

Similar to Vicinitas Therapeutics

Entact BioEntact BioWatertown, MA, USMedicationsest. 2019Entact BioWatertown, MA, US · est. 2019

Entact Bio: A preclinical biotech firm innovating protein function medications with expertise in DUB biochemistry.

Series D · $120.9M38
Vetica LabsVetica LabsSan Diego, CA, USBiotechnologyest. 2013Vetica LabsSan Diego, CA, US · est. 2013

Innovative biotech company in San Diego.

Series A · $4.6M5
Deep Apple TherapeuticsDeep Apple TherapeuticsNew York City, NY, USTherapeuticsest. 2022Deep Apple TherapeuticsNew York City, NY, US · est. 2022

Deep Apple Therapeutics, a biotech startup, rapidly discovers innovative small-molecule therapeutics.

Series A · $52M5
Juvena TherapeuticsJuvena TherapeuticsPalo Alto, CA, USTherapeuticsest. 2017Juvena TherapeuticsPalo Alto, CA, US · est. 2017

Juvena Therapeutics: A biopharmaceutical platform for novel protein-based therapeutics discovery.

Series A · $49.2M11
Frontier Medicines
Frontier Medicines
Series B$244M1282018South San Francisco, CA, US
Co-Founder

Leadership at Frontier Medicines

Chris VarmaChris VarmaBoard Member
Roberto ZoncuRoberto ZoncuCo-Founder
Othman LarakiOthman LarakiBoard Member

Similar to Frontier Medicines

ProFound TherapeuticsProFound TherapeuticsCambridge, MA, USTherapeuticsest. 2022ProFound TherapeuticsCambridge, MA, US · est. 2022

ProFound Therapeutics: Innovating impactful disease understanding and therapeutic creation.

Series A · $75M35
Faze MedicinesFaze MedicinesCambridge, MA, USTherapeuticsest. 2020Faze MedicinesCambridge, MA, US · est. 2020

Faze Medicines: A pioneering biotech company specializing in biomolecular condensate therapeutics.

Series A · $81M40
Totus MedicinesTotus MedicinesEmeryville, CA, USDrug Developmentest. 2020Totus MedicinesEmeryville, CA, US · est. 2020

Totus Medicines: Revolutionizing chemical biology to create life-changing treatments for untreatable diseases.

Series B · $106M40

Daniel Nomura's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Daniel Nomura

Erich FischerErich FischerCo-Founder · Civetta TherapeuticsAlan FriedmanAlan FriedmanCo-Founder · Vita TherapeuticsEric BennettEric BennettFounder · Frontier BioGeorge StamatoyannopoulosGeorge StamatoyannopoulosCo-Founder · Viracta Therapeutics